Professor Marc Riedl joins us to discuss two trials testing oral deucrictibant for hereditary angioedema attacks: one testing deucrictibant as on-demand therapy to treat attacks and the other testing deucrictibant for prophylaxis of attacks.

Dr Julio Delgado and Dr Valentín Ortiz-Maldonado join us to discuss the results of their phase 2 trial testing varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain.

Dr Erica Kaye and Dr Dylan Graetz join us to discuss the importance of qualitative research and how the whole research ecosystem can incorporate and support this type of research to help set the right research questions, and promote the patient voice.

Professor Isabelle Mahé joins us to discuss the results of a post-hoc analysis of the API-CAT trial identifying predictors associated with clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism.

Arnon Kater joins Daniela Marin of The Lancet Haematology to discuss the phase 1b/2 EPCORE CLL-1 trial of epcoritamab monotherapy for Richter transformation, which is being presented at ASH 2025.

Khaled Musallam, Bethany Samuelson Bannow, Mohamad Mohty, David Sallman, and Anna Sureda join us to share their expectations for the upcoming ASH 2025 congress, to be held from 6 to 9 December 2025 in Orlando, on classical and malignant haematology.

Dr. Ruben Mesa joins us to discuss the results of a multicentre, open-label, randomised, active-controlled, phase 3 study of ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia.

Authors join us to discuss their recent Series on advances in genomic techniques that have transformed the diagnosis, prognosis, and targeted treatment of mature T-cell and natural killer-cell lymphoma.

The Lancet Haematology share their thoughts and reflect on their experiences at the European Hematology Association, International Conference on Malignant Lymphoma, and International Society on Thrombosis and Haemostasis meetings.

Paolo Strati joins us to discuss the results of a multicentre, open-label, phase 1 clinical trial of off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractory B-cell lymphoma.